ERBB2 and breast cancer: In the present retrospective study, we adopted an approach aimed at describing both the “quantity” and “quality” of immune response in early-stage HER2-positive breast cancer by exploring the characteristics of baseline BCR and TCR repertoires in the NeoALTTO and CALGB 40601 phase III neoadjuvant clinical trials.